CNCR

Loncar Cancer Immunotherapy ETF [CNCR] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

CNCR Stock Summary

In the News

CNCR Financial details

Company Rating
-
Market Cap
28.74M
Income
-
Revenue
-
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
-
Optionable
No
Shortable
Yes
Earnings
-
P/E
0
Forward P/E
-
PEG
-
P/S
-
P/B
-
P/C
-
P/FCF
-
Quick Ratio
-
Current Ratio
-
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
-8.74%
SMA50
-16.31%
SMA100
-29.01%
Inst Own
-
Inst Trans
-
ROA
-
ROE
-
ROC
-
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
9.22-17.96
52W High
-46.94%
52W Low
+0.22%
RSI
46.36
Rel Volume
-
Avg Volume
34.59K
Volume
Perf Week
1.58%
Perf Month
-2.59%
Perf Quarter
-
Perf Half Y
-34.02%
-
-
-
-
Beta
0.89
-
-
Volatility
0.05%, 0.47%
Prev Close
0%
Price
9.02
Change
0%

Something similar

Top by Market Cap
MSFT
FXAIX
3V64.DE
JPM
MIX.JO
Same Sector
PROT.OL
310960.KS
XLY
CAGG.TO
MCMJW
Same Price Range
600667.SS
FONR
002454.SZ
MOVI3.SA
SAWAD-R.BK
Similar Market Cap
0HA5.L
SRRE
CLCS
ALT.L
WSMGX

Company Profile

Financial Services Asset Management
  • Volume Average 34.59K
  • Market Capitalization 28.74M
  • Headquarters US
  • IPO Date 2015-10-14

The index is composed of the common stock of approximately 30 pharmaceutical or biotechnology companies identified by the fund's index provider, as having a high strategic focus on the development of drugs that harness the body's own immune system to fight cancer. The adviser attempts to invest all, or substantially all, of its assets in the component securities and ADRs that make up the index. At least 80% of its total assets will be invested in the component securities of the index. The fund is non-diversified.